Disinfecting caps are attached to injection ports of needle-free connectors to ensure that needle-free connectors are always clean. These caps protect needleless connectors from contamination, thus reducing the risk of hospital-acquired infections such as the central line blood stream infection (CLABSI). Central line blood stream infection (CLABSI) is the major infection caused due to the usage of central line devices, as it accesses a major vein which is close to the heart. In some severe health conditions, it has to be inserted into the vein for weeks or months thatcan cause central line blood stream infections. Disinfecting caps are used for the prevention of central line-associated bloodstream infection. These caps are widely used to protect the access points/ports of Hemodialysis central venous catheters (HDCVCs). During hemodialysis, the repeated exposure of CVCs to the patients' veins can increase the risk of a Catheter-related Bloodstream Infection (CRBSI) in patients.

Market Dynamics

Increasing incidence of hospital-acquired infections is expected to drive he U.S. disinfecting cap market growth over the forecast period. For instance, in January 2020, according to the data published by t Centers for Disease Control and Prevention, 30,100 Central Line-associated Bloodstream Infections (CLABSIs) occurs in intensive care units and acute care facilities in the U.S. every year. CLABSI is a serious blood-related infection that canprolong hospital stays, and increase the risk of mortality. Increasing incidence of central line-associated bloodstream infections (CLABSIs) and other hospital acquired infections can be controlled and reduced by using disinfecting caps, and this is expected to drive the U.S. disinfecting cap market growth.

Key features of the study:

• This report provides an in-depth analysis of the U.S. disinfecting cap market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. disinfecting cap market based on the following parameters:company highlights, product portfolio, key highlights, financial performance, and strategies

• The key companies covered as a part of this study include ICU Medical, BD, 3M, Merit Medical Systems, Omnia Health, B. Braun SE, Agilent Technologies Inc., Biocrates Lifescience AG, Bio-Rad Laboratories Inc., Pursuit Vascular Inc., and JCM MED
• Insights from this report would allow marketers and management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. disinfecting cap market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. disinfecting cap market

Detailed Segmentation:

• U.S. Disinfecting Cap Market, Application:
  • Central Venous Line
  • Peripheral IV Catheters
  • Others (Blood Collection, etc.)
• U.S. Disinfecting Cap Market, Type:
  • Single Cap System
  • Double Cap System
• U.S. Disinfecting Cap Market, By End User:
  • Hospital and Clinics
  • Ambulatory Surgical Centers
  • Others (Outpatient Surgical Centers, etc.)
• Company Profiles
  • ICU Medical
  • BD
  • 3M
  • Merit Medical Systems
  • Omnia Health
  • Braun SE
  • Agilent Technologies Inc.
  • Biocrates Lifescience AG
  • Bio-Rad Laboratories Inc.
  • Pursuit Vascular Inc.
  • JCM MED